Cerus (NASDAQ:CERS) Insider Richard Benjamin Sells 40,426 Shares of Stock

Cerus Corporation (NASDAQ:CERS) insider Richard Benjamin sold 40,426 shares of the firm’s stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $1.88, for a total transaction of $76,000.88. Following the completion of the transaction, the insider directly owned 879,101 shares of the company’s stock, valued at $1,652,709.88. This represents a 4.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Cerus Stock Performance

Shares of Cerus stock remained flat at $1.93 during trading hours on Monday. The stock had a trading volume of 2,029,960 shares, compared to its average volume of 1,640,307. Cerus Corporation has a 1-year low of $1.12 and a 1-year high of $2.96. The firm has a 50-day moving average of $2.31 and a two-hundred day moving average of $1.86. The company has a current ratio of 1.73, a quick ratio of 1.17 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $370.89 million, a price-to-earnings ratio of -24.13 and a beta of 1.51.

Cerus (NASDAQ:CERS) last announced its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). The business had revenue of $64.58 million for the quarter, compared to analysts’ expectations of $59.31 million. Cerus had a negative return on equity of 26.09% and a negative net margin of 7.58%. Research analysts expect that Cerus Corporation will post -0.08 earnings per share for the current year.

Hedge Funds Weigh In On Cerus

A number of institutional investors and hedge funds have recently modified their holdings of CERS. Vanguard Group Inc. increased its holdings in Cerus by 0.6% in the third quarter. Vanguard Group Inc. now owns 10,783,986 shares of the biotechnology company’s stock valued at $17,147,000 after buying an additional 62,663 shares during the last quarter. Wasatch Advisors LP lifted its holdings in Cerus by 2.6% during the 2nd quarter. Wasatch Advisors LP now owns 8,533,758 shares of the biotechnology company’s stock worth $12,033,000 after buying an additional 213,917 shares during the last quarter. Millennium Management LLC lifted its holdings in Cerus by 17.6% during the 3rd quarter. Millennium Management LLC now owns 3,470,062 shares of the biotechnology company’s stock worth $5,517,000 after buying an additional 519,301 shares during the last quarter. Acadian Asset Management LLC boosted its position in shares of Cerus by 38.6% during the 2nd quarter. Acadian Asset Management LLC now owns 2,632,304 shares of the biotechnology company’s stock worth $3,710,000 after acquiring an additional 733,683 shares in the last quarter. Finally, Ieq Capital LLC boosted its position in shares of Cerus by 1.1% during the 4th quarter. Ieq Capital LLC now owns 2,423,741 shares of the biotechnology company’s stock worth $4,993,000 after acquiring an additional 25,771 shares in the last quarter. Institutional investors and hedge funds own 78.37% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. TD Cowen reiterated a “buy” rating on shares of Cerus in a research note on Monday, January 12th. Wall Street Zen lowered shares of Cerus from a “buy” rating to a “hold” rating in a research note on Saturday. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold”.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.